Skip to main content

Table 5 Safety (most frequent AEs related to REG clinical use) (FAS population, n = 654)

From: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program

Adverse events Any Grade N (%) Grade 3–4 N (%)
Any event 524 (80.1) 286 (43.7)
 Fatigue 271 (41.4) 95 (14.5)
 Hand and Food Skin Reactions 189 (28.9) 59 (9)
 Diarrhea 123 (18.8) 28 (4.3)
 Anorexia 96 (14.7) 19 (2.9)
 Hypertension 72 (11) 30 (4.6)
 Mucositis 72 (11) 8 (1.2)
 Weight loss 33 (5) 4 (<1)
 Rash or desquamation 26 (4) 8 (1.2)
 Thrombopenia 21 (3.2) 1 (<1)
 Muscle pain 9 (1.4) 1 (<1)
 Proteinuria 8 (1.2) 2 (<1)
 Hyperbilirubinemia 7 (1.1) 0